Gossamer Bio
About Gossamer Bio
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
YEAR FOUNDED:
2018
LEADERSHIP:
Founders and CEO: Faheem Hasnain
Founder and COO: Sheila Gujrathi, M.D
115 articles about Gossamer Bio
-
A list of the top 10 biotech IPOs from January to the end of June this year shows significant involvement in the Hong Stock exchange, with five companies based in China, and one, Frontage Holdings, operating in both the U.S. and China.
-
Five Prime Therapeutics Announces the Departure of Dr. Sheila Gujrathi From its Board of Directors
6/9/2019
Five Prime Therapeutics, Inc. announced the departure of Dr. Sheila Gujrathi from the company’s board of directors.
-
Gossamer Bio Announces First Quarter 2019 Financial Results
5/14/2019
Gossamer Bio, Inc. announced its financial results for the quarter ended March 31, 2019 and provided a corporate update.
-
Gossamer Bio to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 14, 2019
5/9/2019
Gossamer Bio, Inc. announced that it will report its first quarter 2019 financial results on Tuesday, May 14, 2019.
-
Gossamer Bio Secures Debt Facility for up to $150 Million
5/2/2019
Gossamer Bio, Inc. announced it entered into a five-year senior debt facility led by MidCap Financial.
-
Gossamer Bio Announces Participation in Bank of America Merrill Lynch Health Care Conference 2019
5/1/2019
Gossamer Bio, Inc. announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will participate in a fireside chat at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14 at 1:00 p.m. PT.
-
Gossamer Bio Announces 2018 Annual Financial Results
3/22/2019
Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the year ended December 31, 2018 and provided an update on recent corporate developments.
-
A summary of IPOs from companies in the biotech and pharma world since February 1, 2019.
-
Gossamer Bio Announces Participation in Upcoming Investor Conferences
2/22/2019
Gossamer Bio, Inc. announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will present at the following upcoming investor conferences:
-
Gossamer Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2/12/2019
Gossamer Bio, Inc. announced the closing of its previously announced initial public offering of 19,837,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,587,500 additional shares, at a price to the public of $16.00 per share.
-
Gossamer Bio has been the poster child for biotech companies struggling with IPO launches during the shutdown.
-
Gossamer Bio Announces Pricing of Initial Public Offering on February 8, 2019
2/7/2019
Gossamer Bio, Inc. announced the pricing of its initial public offering of 17,250,000 shares of common stock at a public offering price of $16.00 per share.
-
The government shutdown threw a wrench into several biotech company’s plans for initial public offerings (IPOs). Although the government is only guaranteed to stay open until February 15, several biotechs are working to get their IPOs launched in that window. Here’s a look.
-
The area is home to numerous well-known players in the pharma industry, including Abbott, Iovance, Gossamer Bio, Crown Biosciences, Illumina, Human Longevity and many, many more.
-
You have to give San Diego-based Gossamer Bio credit for the way it’s adapted its plans for an initial public offering (IPO) to deal with the government shutdown.
-
A summary of IPOs from companies in the biotech and pharma world since January 1, 2019.
-
Gossamer Bio Announces Updates Regarding its Initial Public Offering
1/30/2019
Gossamer Bio, Inc. announced that it has filed an amended registration statement on Form S-1 with the U.S. Securities and Exchange Commission in connection with its proposed initial public offering of its common stock.
-
Numerous biotech companies had filed for initial public offerings (IPOs) during the five-week government shutdown, but were unlikely to actually be able to be listed until the U.S. Securities and Exchange Commission (SEC) had a chance to review their filings.
-
San Diego-based Gossamer Bio is pulling the trigger on an initial public offering by harnessing a legal loophole that will allow the company to move forward with its listing plans despite the partial government shutdown, now in its 34th day.
-
Gossamer Bio Announces Commencement of Initial Public Offering
1/23/2019
Gossamer Bio, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the commencement of a proposed initial public offering of its common stock.